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Hemoglobin (Hb) may impact the transduction of endothelium-dependent and nitric oxide (NO) 41 
mediated vasodilator activity, given its contribution to shear stress stimuli and diverse biochemical 42 
reactions with NO. We hypothesized that an acute reduction in [Hb] and hematocrit (Hct) would 43 
increase brachial artery flow-mediated dilation (FMD). In eleven healthy males (28±7 years; 23±2 Kg · 44 
m
-2
), FMD (Duplex ultrasound), arterial blood gases, Hct and [Hb], blood viscosity, and NO metabolites 45 
(ozone-based chemiluminescence) were measured before and after isovolumic hemodilution, where 46 
~20% of whole blood was removed and replaced with 5% human serum albumin. Hemodilution reduced 47 
Hct by 18±2% (P<0.01) and whole blood viscosity by 22±5% (P<0.01). Plasma nitrite, S-nitrosothiols, 48 
and total red blood cell NO were collectively reduced by ~15-40% (P<0.05 for all). Brachial artery FMD 49 
increased by ~160% from 3.8±2.1 to 9.7±4.5% (P<0.01). Statistical covariation for the shear stress 50 
stimulus did not alter FMD, indicating that the increase in FMD was not directly related to alterations in 51 
whole blood viscosity and the shear stimulus. Collectively, these findings indicate that hemoglobin 52 
scavenging of NO appears to be an important factor in the regulation of FMD under normal conditions 53 
through constraint of endothelium-dependent NO-mediated vasodilation in healthy humans. 54 
  55 
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KEY POINTS SUMMARY 56 
 Changes in hematocrit influence nitric oxide signaling through alterations in shear stress stimuli 57 
and hemoglobin scavenging of nitric oxide; these two regulatory factors have not been assessed 58 
simultaneously 59 
 Isovolumic hemodilution led to a marked increase in brachial artery flow-mediated dilation in 60 
humans 61 
 The increase in flow-mediated dilation occurred in the face of an unaltered shear stress stimulus 62 
for vasodilation and reduced resting steady-state nitric oxide levels in the blood 63 
 Collectively, our data point towards hemoglobin scavenging of nitric oxide as a key regulatory 64 
factor of brachial flow-mediated dilation and highlight the importance of simultaneous 65 
consideration of nitric oxide production and inactivation when investigating vascular function in 66 
humans 67 
 68 
  69 




The endothelium is a single cell layer that lines the adluminal surface of the vasculature. The 71 
production of autocoids within the endothelium and paracrine signaling contribute to vascular 72 
homeostasis with endothelial function related to cardiovascular risk (Green et al., 2011). The 73 
prototypical pathway by which the endothelium regulates blood flow is through nitric oxide (NO) 74 
bioactivation (Ignarro et al., 1987; Palmer et al., 1987). Also implicated in the transduction of NO 75 
signaling is hemoglobin (Hb), through its independent influence on NO transport/release, NO 76 
scavenging, and rheological properties of the blood (i.e. whole blood viscosity) that impact 77 
mechanotransduction of shear stress. Therefore, alterations in hematocrit (Hct) and the concomitant 78 
changes in [Hb] and whole blood viscosity would be expected to greatly impact endothelium dependent 79 
NO-mediated vasodilation. 80 
Shear stress is the tangential force exerted on the endothelium by blood flow. Acute changes in 81 
shear stress lead to mechanotransduction of signaling processes (Lansman et al., 1987; Tessier-Lavigne 82 
et al., 1988) that govern NO formation and vasorelaxation (Pohl et al., 1986; Rubanyi et al., 1986; 83 
Green et al., 2014), a process termed flow-mediated dilation (FMD). These signaling pathways have 84 
been well characterized (Green et al., 2017); however, what often evades experimental consideration is 85 
the persistent use of shear rate as a surrogate for shear stress (Leo et al., 2019). While shear rate is 86 
related to the diameter of a vessel and the velocity of the blood flowing through it, shear stress further 87 
takes into account the important role of blood viscosity. The viscosity of blood impacts the force exerted 88 
on the endothelium, mechanotransduction (Ando et al., 1993), and hence should directly alter FMD 89 
(Melkumyants et al., 1989; Melkumyants & Balashov, 1990). 90 
In this regard, Hct would be expected to influence FMD given its relationship with whole blood 91 
viscosity (Tremblay et al., 2019b). In addition to the role of Hct in determining shear stress, Hb is 92 
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intimately intertwined in NO biochemistry. In vitro work has demonstrated that a decrease in Hct from 93 
50% to 15% triples the half-life of NO (Azarov et al., 2005) due to reduced NO scavenging by Hb. 94 
However, Hb can also protect and convey NO bioactivity through the formation of S-nitrosothiols 95 
(Doctor & Stamler, 2011) and/or deoxyhemoglobin mediated reduction of NO2
− to form NO (Kim-96 
shapiro et al., 2006). Therefore, changes in Hct (and [Hb]) may influence NO bioactivation 97 
independently from its influence on the shear stress stimulus of an FMD test.  98 
Previous studies have demonstrated inconsistent results related to the influence of Hct/[Hb] on 99 
FMD. An inverse correlation between [Hb] and FMD has been reported in both healthy individuals 100 
(Madsen et al., 2006) and chronic kidney disease patients with (Sonmez et al., 2010) and without type II 101 
diabetes (Yilmaz et al., 2009). However, within participants that have undergone an experimental 102 
manipulation of [Hb], a proportional relationship between [Hb] and FMD has been described whereby 103 
decreases in [Hb] reduced FMD in hemochromatosis patients (Giannattasio et al., 2002a), and increases 104 
in [Hb] increased FMD in end stage renal failure patients (Verbeke et al., 2007). Further, it was recently 105 
demonstrated that a ~2% reduction in Hct had no effect on FMD in middle-aged, overweight individuals 106 
without any additional co-morbidities (Gnasso et al., 2019). Overall, the relatively small changes in 107 
Hct/[Hb] and/or presence of co-morbidities in these latter studies makes reconciliation of these 108 
conflicting data problematic. Additionally, none of the aforementioned studies assessing the impact of 109 
Hct/[Hb] on FMD provided indices of NO bioavailability or coupled measurements of blood viscosity 110 
with appropriate statistical adjustments (Atkinson et al., 2009, 2013) for shear stress area under the 111 
curve [the stimulus for FMD (Pyke & Tschakovsky, 2007)] in their analyses. Recently, our research 112 
group demonstrated that large (~15%) reductions in [Hb] through isovolumic hemodilution of high-113 
altitude Andean natives with excessive erythrocytosis increases FMD (Tremblay et al., 2019b), 114 
however, whether this is a fundamental relationship that persists in the absence of pathology (e.g. 115 
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polycythemia) and without chronic hypoxemia in healthy humans remains unknown. Given these 116 
previous results we speculate that reduced Hb-mediated NO scavenging following isovolumic 117 
hemodilution would improve FMD irrespective of the potential for a reduced shear stress stimulus. 118 
Further, whether the shear stress stimulus is actually reduced is not clear given post-occlusive flow may 119 
be elevated due to decrease in resistance consequent of reduced viscosity with hemodilution. 120 
In this study of healthy humans we aimed to comprehensively assess the influence of Hct/[Hb] 121 
on FMD. To address our hypotheses we utilized isovolumic hemodilution to reduce Hct and measured 122 
arterial NO bioavailability and blood viscosity along with FMD prior to and following this intervention. 123 
We hypothesized that FMD would be increased following hemodilution, with this increase occurring 124 
independent of any changes in resting steady-state NO bioavailability.  125 
 126 
METHODS 127 
Ethical Approval 128 
This study was approved by the Clinical Research Ethics Board of the University of British 129 
Columbia (H16-01028). All participants gave written informed consent in English prior to participating. 130 
This study conformed to the standards set by the Tri-Council Policy Statement: Ethical Conduct for 131 
Research Involving Humans (TCPS 2) and Declaration of Helsinki, except for registration in a database.  132 
Eleven healthy males were recruited to participate in this study (28±7 years of age; 177±4 cm in 133 
height; 72±6 kg in weight; BMI of 23±2 kg · m
-2
). All participants were recruited at the University of 134 
British Columbia’s Okanagan campus. Participants were free of cardiovascular, respiratory and 135 
neurological disease, and were non-smokers.  136 




Protocol Overview 138 
Participants arrived at the laboratory having abstained from alcohol, caffeine and exercise for 24 139 
hours, were fasted for a minimum of 4 hours, but drank water ad libitum. Half the participants began the 140 
protocol at 0600 h and the other half at 1300 h.  141 
Upon arrival, participants assumed the supine position and were instrumented with a radial artery 142 
and ante-cubital venous catheter (see below). Twenty minutes was provided for subjects to rest 143 
following cannulation, at which time the rest of the experimental set-up was performed. Following 144 
instrumentation and ~5 min of baseline measurements (heart rate, HR; mean arterial pressure, MAP; 145 
stroke volume, SV; cardiac output, CO; and blood sampling) a FMD test was performed. 146 
Echocardiography (SV, CO) was performed to determine if isovolumic hemodilution influenced central 147 
hemodynamic for the purposing of aiding in interpretation of our study. Whole blood was then 148 
transferred into an Anticoagulant Citrate Phosphate Dextrose Solution BLOOD-PACK
TM
 (4R0012MC, 149 
Fenwal, USA) through a non-pyrogenic plasma transfer kit (4C2240, Fenwal, USA) to collect up to 450 150 
mL of whole blood per BLOOD-PACK. This hemodilution protocol was conducted in two stages aimed 151 
at removing/replacing blood in 10% increments (i.e., 10% of whole blood volume per stage). Thus, a 152 
total of approximately 20% of whole blood was removed and then replaced with an equal volume of 5% 153 
human serum albumin (Alburex® 5%). Repeat arterial blood sampling allowed for the tracking of 154 
changes in Hct, which were taken to reflect the extent to which we had successfully removed and 155 
replaced whole blood. For example, a 10% reduction in Hct following the removal and replacement of 156 
equal volumes of whole blood and 5% serum albumin respectively was inferred to indicate the removal 157 
and replacement of 10% of whole blood. The duration of the hemodilution protocol was ~1.5-2 hours. 158 
The second FMD test and blood sampling was conducted 30 minutes following completion of the 159 
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hemodilution protocol (~4 hours following the baseline FMD). A secondary study assessing FMD prior 160 
to and following 4-hours of rest was conducted in a separate cohort as a time control. 161 
 162 
Experimental methods 163 
Catheterization 164 
Using sterile technique, a 20G arterial catheter (Arrow, Markham, ON) was advanced into the 165 
left radial artery under local anesthesia (Lidocaine, 1.0%) and ultrasound guidance. The radial artery 166 
catheter was attached to an in-line and waste-less sampling system (VAMP system, Edwards Life 167 
Sciences). This allows for serial blood sampling and the continuous measurement of radial arterial blood 168 





, Becton Dickinson, USA) was then inserted into an ante-cubital vein (for albumin 170 
infusion). 171 
 172 
Flow Mediated Dilation 173 
Brachial artery FMD was measured in accordance with internationally-accepted guidelines 174 
(Thijssen et al., 2011). Briefly, a one-minute recording of baseline arterial diameter and blood velocity 175 
was recorded, followed by a five-minute suprasystolic cuff occlusion (220 mmHg). The brachial artery 176 
cuff was placed immediately distal to the epicondyles. Vessel imaging was always performed proximal 177 
to the cuff. Recording resumed 30-seconds prior to deflation and continued for three minutes post cuff 178 
deflation. All measurements were acquired with a 10 MHz multi-frequency linear array probe (15L4 179 
Smart Mark, Teratech, USA) attached to a high-resolution ultrasound machine (Terason uSmart 3300). 180 
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The angle of insonation for the acquisition of velocity was 60°. The ultrasound recordings were saved as 181 
a video files (Camtasia Studio, Techsmith Co, Ltd, USA) for future analysis using edge-detection 182 
software.(Woodman et al., 2001) The video files were anonymized prior to determination of FMD. The 183 
within day coefficient of variation for our sonographer is <10% (Tremblay et al., 2019a). 184 
Shear stress was calculated as the product of shear rate (4*peak envelope blood velocity / arterial 185 
diameter) and whole blood viscosity at a shear rate of 225 s
-1
. The FMD stimulus was quantified as the 186 
shear stress area under the curve (SSAUC) from cuff deflation to peak diameter (Pyke & Tschakovsky, 187 
2007). Reactive hyperemia (3-min) and reactive hyperemia over the first minute post cuff deflation were 188 
calculated as mL of blood flow while peak reactive hyperemia was calculated as the peak blood flow 189 
rate following cuff deflation (i.e. mL/min) (Limberg et al., 2020; Rosenberry & Nelson, 2020). 190 
Antegrade and retrograde shear stress were calculated as shear stress in the forward (positive) and 191 
backward (negative) direction, respectively, and mean shear stress as the sum of antegrade and 192 
retrograde (time-averaged mean shear stress). The oscillatory shear index (OSI) was calculated as 193 
|retrograde shear stress| / (|antegrade shear stress| + |retrograde shear stress|). Blood flow (mL/min) was 194 
calculated as peak envelope blood velocity / 2 * (π(0.5*diameter)
2
). Vascular resistance was calculated 195 
as MAP / blood flow. 196 
 197 
Echocardiography 198 
Stroke volume was estimated from the cross sectional area of the left ventricular outflow tract in a 199 
parasternal long axis view and pulsed wave Doppler recordings acquired from the apical five chamber 200 
image. All images were acquired by a single experienced sonographer (MS) in accordance with the 201 
American Society of Echocardiography guidelines (Lang et al., 2015) on a commercially available 202 
ultrasound machine (Vivid E9, GE Healthcare, Piscataway, NJ, USA). Three consecutive cardiac cycles 203 
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were analysed offline (Echopac, GE Healthcare, Piscataway, NJ, USA) and averaged. Stroke volume 204 
was calculated as the product of the velocity-time integral and aortic area, which was then multiplied by 205 
heart rate obtained from the lead II electrocardiogram inherent to the ultrasound to derive cardiac output. 206 
 207 
Blood Sampling & Analyses 208 
Prior to and following hemodilution, ~1.0 mL of radial arterial blood was drawn into a pre-209 
heparinized syringe (SafePICO, Radiometer, Copenhagen, Denmark) and analyzed immediately at 37°C 210 
using a commercial blood gas analyzer (ABL90 FLEX, Radiometer). This analysis included 211 
measurement of the partial pressure of arterial oxygen (PaO2), the partial pressure of arterial carbon 212 
dioxide (PaCO2), arterial oxygen saturation (SaO2), arterial oxygen content (CaO2), pH, bicarbonate ion 213 
concentration [HCO3
-
], [Hb] and Hct. Arterial blood was also analyzed for whole blood viscosity. 214 
Arterial blood was drawn into a Lithium Heparin Vacutainer® (Becton Dickinson, USA). Blood 215 
viscosity was measured in duplicate within 15 minutes of blood sample acquisition at a shear rate of 225 216 
s
-1
 at 37.0°C with a cone-and-plate viscometer (Model DV2T, Brookfield Amtek, USA) (Baskurt et al., 217 
2009). Further, a separate ex vivo study was conducted to determine the influence of hemodilution with 218 
5% human serum albumin on plasma viscosity (see below).  219 
Arterial blood was also drawn into a K2EDTA Vacutainer® (Becton Dickinson, USA). Whole 220 
blood was then immediately centrifuged at 600 g for 10 minutes at a temperature of 4.0°C. Plasma and 221 
packed red blood cells were then aliquoted into cryovials, flash frozen in liquid N2, and stored at -80°C. 222 
Samples were then shipped on dry ice to the UK using a commercial clinical science logistics company 223 
(Marken, Durham, NC, USA). Temperature tracking indicated samples remained at -78.5°C throughout 224 
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transport. There, plasma and red blood cell NO were measured using tri-iodide reductive ozone based 225 
chemiluminescence as previously described for our research group (Bailey et al., 2017). 226 
 227 
Plasma S-Nitrosothiols (PL-RSNO): Plasma (540 μL) was mixed with 5% acidified sulphanilamide (60 228 
μL) and left to incubate in the dark at 21°C for 15 min to remove NO2
− before injection into the tri-iodide 229 
reagent for direct measurement of RSNO. 230 
 231 
Plasma Nitrite (PL-𝑁𝑂2
−): A separate sample (200 μL) was injected into the tri-iodide reagent for the 232 
combined measurement of NO2
− and RSNO with NO2
− calculated by subtracting the concentration of 233 
RSNO.  234 
 235 
Red Blood Cell NO (RBC-NO): The original tri-iodide solution was modified with the addition of 236 
potassium ferricyanide [K3Fe
III
(CN)6] to limit auto-capture of NO (Rogers et al., 2005). The packed red 237 
blood cells were lysed 1:4 in EDTA (0.5 mM; pH corrected to 7.0) and incubated for 5 min on ice 238 
(Rogers et al., 2005). A 400 μL sample was then injected into the modified tri-iodide reagent for the 239 
measurement of total RBC-NO. 240 
All calculations were performed using Origin/Peak Analysis software. All chemicals were of the 241 
highest purity available from MilliporeSigma. Whole blood [NO] was subsequently calculated as: ((1-242 
Hct) x plasma [NO]) + (Hct x RBC [NO]). 243 
 244 
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Time control flow-mediated dilation experiment 245 
To account for changes in FMD that may occur during supine rest, we enrolled 11 male participants 246 
(age: 28±6 years; height: 180±4cm; weight: 76±9kg) into a time control study (separate cohort from 247 
primary study). Participants had their brachial FMD assessed as described in the main experimental 248 
protocol. Following 20-minutes of supine rest, a baseline FMD test was conducted. Subjects then rested 249 
for 4 hours, with their upper body at a 45° incline. Following this period, the supine position was re-250 
assumed for 20-minutes prior to the post-test FMD. Blood pressure (brachial sphygmomanometer), heart 251 
rate, and blood viscosity (Cone and plate viscometer) were also measured prior to and following the 252 
resting period (as described previously).  253 
Ex vivo blood viscosity experiment 254 
To determine the influence of whole blood replacement with 5% human serum albumin on plasma 255 
viscosity a follow up ex vivo study was conducted. Data from 7 young healthy adult males was included 256 
(age: 27±3 years; height: 176±6 cm; weight: 71±6 kg). 257 
 258 
Blood was collected from the medial ante-cubital vein into two lithium heparin Vacutainers ® (Becton 259 
Dickinson, USA). Blood from each tube was measured under the following conditions: 260 
Tube 1: Control blood 261 
1) Whole Blood: Whole blood viscosity was measured. 262 
2) Plasma: Whole blood was centrifuged at 600 g and 4°C for 10 minutes. Viscosity of the 263 
separated plasma was then measured. 264 
Tube 2: Hemodiluted blood 265 
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1) Whole Blood: 4 mL of whole blood was transferred to a conical tube and 1 mL of 5% human 266 
serum albumin was added (i.e. 20% hemodilution). This blood was thoroughly mixed and 267 
subsequently whole blood viscosity of the diluted blood was assessed. 268 
2) Plasma: Blood that had been diluted by 20% was centrifuged at 600 g and 4°C for 10 minutes. 269 
Viscosity of the separated plasma was then measured. 270 
For all samples, viscosity was measured in duplicate and within 30 minutes of blood sample acquisition 271 
at a shear rate of 225 s
-1
 at 37.0°C with a cone-and-plate viscometer (Model DV2T, Brookfield Amtek, 272 
USA). Hematocrit was also measured to confirm the magnitude of hemodilution. 273 
 274 
Statistical Analyses 275 
Statistical analyses were completed in SPSS (IBM, V24). All pre- to post-hemodilution 276 
comparisons were made using a paired two-tailed t-test. To account for differences in FMD stimulus, 277 
testing was also performed with SSAUC included as a covariate in linear mixed model analysis. 278 
Furthermore, allometric scaling was performed to account for differences in baseline diameter within 279 
participants. Briefly, the diameter change on a logarithmic scale (ln(peak diameter) - ln(baseline 280 
diameter)) was assessed as the outcome variable in a linear mixed model with logarithmically-281 
transformed baseline diameter included as a covariate (Atkinson & Batterham, 2013; Atkinson et al., 282 
2013). The time control experiment followed the same statistical analyses described above. For the ex 283 
vivo blood viscosity experiment, data were compared pre to post hemodilution using two-tailed paired t-284 
tests. 285 
 286 




Resting Hematological and Hemodynamic variables 288 
Following hemodilution, [Hb] (13.9±0.7 vs 11.4±0.6 g/dL; P<0.01) and Hct (43.7±2.3 vs. 289 
34.8±1.7 %; P<0.01) both decreased by 18±2%, which coincided with a 22±3% reduction in arterial 290 
whole blood viscosity (3.54±0.24 vs. 2.80±0.22 cP; P<0.01; Figure 1A&B). Due to the reduction in 291 
[Hb], CaO2 was reduced by 18±2% (Figure 1C), while PaO2 (95±7 vs. 92±4 mmHg; P=0.08) and SaO2 292 
were unaltered (97.7±0.7 vs. 97.6±0.4 %; P=0.59). Whole blood [NO] was reduced by 32±17% 293 
following hemodilution (135.3±42.0 vs. 89.0±18.2 nmol/L; P<0.01)(Figure 1E). This was due to a 294 
22±22% reduction in plasma [NO2
−] (105.7±37.0 vs. 79.9±21.1 nmol/L; P=0.01)(Figure 1F), 16±55% 295 
reduction in plasma [RSNO] (6.5±3.2 vs. 4.4±2.0 nmol/L; P=0.03)(Figure 1G), and 37±17% reduction 296 
in total red blood cell [NO] (151.0±67.6 vs 89.1±30.2 nmol/L; P<0.01)(Figure 1H). There was an 297 
increase in PaCO2 (39.9±1.5 vs. 41.6±1.8 mmHg; P<0.01), decrease in [HCO3
−] (25.2±1.2 vs. 24.4±0.8 298 
mmol/L; P=0.01), and decrease in pH (7.41±0.01 vs. 7.38±0.02; P<0.01) following hemodilution.  299 
Hemodilution did not alter MAP (99.8±6.6 vs. 97.0±7.2 mmHg; P=0.15). Similarly, HR (62±13 300 
vs. 64±12 bpm; P=0.26), SV (61.9±11.8 vs. 64.3±15.3 mL; n=8; P=0.52) and CO (3.74±0.75 vs. 301 
3.95±0.81 L/min; n=8; P=0.52) were unaltered following hemodilution. 302 
Neither mean (39.6±17.1 vs. 52.7±31.0 mL · min
-1
; P=0.23), antegrade (52.0±17.5 vs. 66.3±26.2 303 
mL · min
-1
; P=0.15) or retrograde (-12.4±8.6 vs. -13.6±11.2 mL · min
-1
; P=0.51) brachial artery blood 304 
flow were altered following hemodilution. Likewise, forearm vascular resistance (3.03±1.47 vs 305 




; P=0.52) and shear stress patterns were unaltered following 306 
hemodilution (Figure 2A), which was reflected in an unaltered brachial artery OSI (0.19±0.10 vs. 307 
0.18±0.14; P=0.80). 308 




Reactive hyperemia responses 310 
Reactive hyperemia responses prior to and following hemodilution are presented in Table 1 and 311 
Figure 2B. Total reactive hyperemia (ml; +57.8±77.7%; P=0.02) and reactive hyperemia within one-312 
minute post cuff deflation (ml; +42.9±50.1%; P=0.02) were increased following hemodilution, while 313 
changes in the peak reactive hyperemia (ml/min) following hemodilution did not reach statistical 314 
significance (+24.8±35.1%; P=0.056; Table 1). The resulting SRAUC for the brachial artery was 315 
elevated following hemodilution (19,314±7,642 vs. 34,410±19,159; P=0.02; Figure 2C); however, 316 
given the lower viscosity post hemodilution, SSAUC was not significantly altered pre to post 317 
hemodilution (686±286 vs. 943±525; P=0.12; Figure 2B&D).  318 
 319 
Flow mediated dilation 320 
Brachial FMD was increased by ~160% following hemodilution (3.8±2.1 vs 9.7±4.5%; P<0.01). 321 
Inclusion of SSAUC and baseline diameter as covariates did not alter the observed changes, with the 322 
adjusted FMD still increasing by ~120% from 4.2±3.0 to 9.2±3.0% (P<0.01) (Figure 2E). As the time to 323 
peak dilation of the brachial artery was longer following hemodilution (Table 1), we also standardized 324 
SSAUC (to 60-seconds following cuff deflation) to further assessed changes in FMD (SSAUC-60; 325 
Table 1). With inclusion of baseline diameter and SSAUC-60 as covariates the increase in FMD with 326 
hemodilution persisted (3.9±0.9 vs. 9.5±0.9%; P<0.01). 327 
 328 
Time Control Flow-mediated Dilation Experiment 329 
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Neither mean arterial pressure (MAP; 81±4 vs. 84±7 mmHg; P=0.42) nor heart rate (56±11 vs. 53±11; 330 
P=0.14) were different pre-to post the time control rest period. Blood viscosity was also unaltered 331 
(3.88±0.30 vs 3.88±0.44 cP; P=0.99; Figure 3A). Mean shear was reduced from 133±83 to 67±31 s
-1
 332 
(P<0.01), antegrade shear was reduced from 147±79 to 91±34 s
-1
 (P=0.01), while retrograde shear 333 
increased from -13±14 to -24±23 s
-1
 (P=0.03; Figure 3B). Shear rate was reported given that viscosity 334 
was not altered in the time control period. Following the time control period, SRAUC was reduced from 335 
31167±8483 to 24647±6456 (P=0.04) but FMD remained unaltered (8.2±3.7 vs. 7.5±3.8%; P=0.50; 336 
Figure 3D). Indeed, even following inclusion of the SRAUC stimulus as a covariate (Figure 3C), there 337 
was no alteration in FMD following the four hour time control period (8.0±3.7 vs. 7.7±3.7%; P=0.76). 338 
 339 
Ex Vivo Blood Viscosity Experiment 340 
Hematocrit was reduced from 44.9±2.4% to 35.9±2.4% following ex vivo hemodilution, which 341 
represented a 20.10±0.01% change. Viscosity data are presented in Table 2. Hemodilution with 5% 342 
human serum albumin reduced plasma viscosity from 1.33±0.04 to 1.17±0.5 cP (P<0.001). 343 
  344 




This study demonstrates that acute reductions in Hct following isovolumic hemodilution increase 346 
brachial artery FMD in healthy humans. The observed increase in brachial FMD occurs independent of 347 
the impact of Hct on shear stress and despite a reduction in resting whole blood, plasma, and red blood 348 
cell NO bioavailability. These findings are evidenced by an unaltered SSAUC following hemodilution 349 
as well as reductions in whole blood, plasma, and red blood cell NO bioavailability. Collectively, these 350 
data point towards hemoglobin scavenging of NO as an important factor in the regulation of FMD in 351 
healthy humans. 352 
 353 
Comparison to previous studies 354 
Previous studies have demonstrated an inverse correlation between [Hb] and FMD across cohorts 355 
of healthy (Madsen et al., 2006) individuals and those with chronic kidney disease (Yilmaz et al., 2009; 356 
Sonmez et al., 2010). However, interventional studies conversely support the notion that reductions in 357 
[Hb] impair FMD in hemochromatosis patients (Giannattasio et al., 2002b), while increases in [Hb] 358 
improve FMD in end stage renal failure (Verbeke et al., 2007). Only recently did we consistently 359 
demonstrate, both between and within participants, that a lower [Hb] is associated with higher FMD in 360 
an Andean highlander population with polycythemia (Tremblay et al., 2019b). However, the collectively 361 
equivocal nature of these previous studies is complicated by the differing patient populations tested and 362 
the variable Hct values these populations exhibit. For the first time in healthy humans, utilizing 363 
experimental hemodilution to reduce Hct under normoxic laboratory conditions, our study provides 364 
confirmatory evidence that a lower Hct is related to a higher FMD. We further extend these findings, to 365 
demonstrate that this increase in FMD occurs despite reductions in resting steady state NO 366 
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bioavailability (whole blood, plasma, and red blood cell) and statistical covariation for the SSAUC 367 
stimulus. That there were no changes in central hemodynamics (i.e. SV & CO) following isovolumic 368 
hemodilution and our time control data indicate changes in FMD were unrelated to a prolonged period 369 
of rest both strengthen our finding of increased FMD following hemodilution. 370 
 371 
Potential mechanism(s) of improved FMD 372 
Previous work has aimed to partition the influence of blood viscosity from Hb on blood flow 373 
regulation by differential manipulations of plasma viscosity during hemodilution. Indeed, in pre-clinical 374 
models when hemodilution is produced with both a low and high viscosity plasma expander, 375 
vasodilation occurs with increased plasma viscosity whereas vasoconstriction ensues when plasma 376 
viscosity is unaltered (Tsai et al., 1998, 2005). This vasodilation following administration of a high 377 
viscosity plasma expander is associated with a greater shear stress-mediated formation of NO (Tsai et 378 
al., 2005). However, in the current study, hemodilution with 5% human serum albumin reduces plasma 379 
viscosity (Table 2) concurrent to reduced whole blood viscosity (Figure 1B), which points to reduced 380 
hemoglobin scavenging versus increased plasma dependent shear mediated NO production as the 381 
mechanism by which hemodilution increases FMD in humans. In further support of this notion is the 382 
reduction in plasma NO2
− following hemodilution (Figure 1F). This reduction in NO2
− likely indicates a 383 
reduction in NOS activity in the resting state (Lauer et al., 2001; Kleinbongard et al., 2003), which 384 
would be expected to impair – not improve – FMD. Importantly, such a reduction in NOS activity in the 385 
resting state may not necessarily reflect the potential for endothelial NOS dependent activation in the 386 
context of elevated shear stress (see next paragraph). The SSAUC stimulus was not different between 387 
the pre- and post-hemodilution FMD protocols, indicating the stimulus for endothelial NOS mediated 388 
NO production was also likely not different. 389 
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Previous investigation examining an in situ lung perfusion model demonstrated similar 390 
potentiation of NO mediated vasodilation with lower Hct (i.e. [Hb])(Deem et al., 1998) to that of the 391 
current study. The potentiated vasodilation observed by Deem et al., was validated as an NO dependent 392 
scavenging mechanism effect via NOS blockade (Deem et al., 1998). Similar to the present study, 393 
potentiated vasodilation occurred without a simultaneous increase in blood [NO2
−], highlighting that the 394 
potential role of scavenging is related to constraint of transiently liberated NO not detected by ‘steady-395 
state’ blood measurements (in the study by Deem et al., 1998 this NO production was measured through 396 
analysis of expirate)(Deem et al., 1998). Therefore, while it was not possible to directly quantify 397 
alterations in NO scavenging in vivo, the evidence for this physiological phenomenon (Deem et al., 398 
1998; Azarov et al., 2005) coupled with the link between FMD and NO (Green et al., 2014), suggest the 399 
observed increase in FMD herein is due in large part to reductions in Hb scavenging of the NO that is 400 
transiently produced following the post-occlusive shear stimulus. 401 
 Previous in vitro work demonstrated a tripling of NO’s half-life when Hct was lowered from 402 
50% to 15% (Azarov et al., 2005). However, interpretation of our data require further consideration of 403 
important in vivo hemodynamic factors. Reductions in Hct increase the cell free layer at the abluminal 404 
wall of microvessels (Sriram et al., 2011), which is related to the axial migration of red blood cells that 405 
occurs under conditions of laminar flow (Goldsmith & Mason, 1961). This would be expected to impose 406 
a greater diffusional limitation for Hb scavenging of NO and increases its half-life following 407 
hemodilution (Kim-shapiro et al., 2006). Moreover, the important influence of the unstirred layer 408 
surrounding red blood cells is also another potential factor associated with Hct mediated alterations in 409 
NO scavenging by Hb (Kim-shapiro et al., 2006). While our data suggests reduced NO scavenging may 410 
underpin the observed increases in FMD with isovolumic hemodilution, the specific factors that 411 
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contribute to this effect and their relative importance in larger vessels such as the brachial artery (not 412 
microvessels in which these relationships are defined) are not discernible in the present study. 413 
 414 
Experimental Considerations 415 
Recent work has highlighted the importance of considering blood viscosity across a range of shear 416 
rates that reflect in vivo hemodynamics for the accurate quantification of shear stress and corresponding 417 
implications for vasodilation. Indeed, as shear rate increases, blood viscosity decreases as a function of 418 
the non-Newtonian nature of whole blood (i.e. shear thinning) (Leo et al., 2019). In the present study, 419 
whole blood viscosity was determined at a single shear rate of 225 s
-1
; however, if a shear thinning 420 
profile had been applied to each participant and incorporated into their SSAUC calculation, one would 421 
expect the SSAUC post-hemodilution to be comparatively lower than that reported herein given the 422 
increase in SRAUC following hemodilution (i.e. a greater level of shear thinning than pre-423 
hemodilution). A potentially lower SSAUC than that reported would be reflected in an even greater 424 
FMD post-hemodilution following adjustment for the SSAUC stimulus. Further, it is important to 425 
address that females were not tested in the present study and future work should aim to determine the 426 
influence of [Hb] on FMD in females. Given the observed role of [Hb] on FMD, and that the impact of 427 
NOS inhibition on NO scavenging has been demonstrated as dependent upon Hct (or [Hb])(Deem et al., 428 
1998) raises the possibility that variability in the proportion of FMD that is attributed to NO (Green et 429 
al., 2014) may be potentially due in part to variability in Hct within these study cohorts. 430 
There is considerable debate surrounding the notion that hyper versus hypo-viscosity may be more 431 
appropriate for optimal cardiovascular function (Forconi & Gori, 2009; Salazar Vázquez et al., 2010). 432 
While the specifics of this debate are beyond the scope of this investigation, it is important to note that 433 
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much of the pertinent literature is limited by the use of volume expanders that do not properly mimic the 434 
complex functions of Hb (e.g. NO scavenging). Further, human studies that are considered in this 435 
debate, as previously mentioned, do not appropriately account for the collective influence of Hct on 436 
shear stress and NO [e.g. (Giannattasio et al., 2002a)]. Thus, moving forward, it is clear that 437 
consideration of viscosity in isolation is inappropriate and that a view for how the integrated influence of 438 
changes in blood viscosity, NO bioavailability, and Hb scavenging coalesce to regulate FMD as 439 
demonstrated herein requires consideration in the hyper- versus hypo-viscosity debate.  440 
 441 
CONCLUSION 442 
Our study demonstrates that acute reductions in hemoglobin concentration increase brachial artery flow-443 
mediated dilation in humans. This increase occurs while accounting for alterations in the shear stimulus 444 
for flow-mediated dilation and despite reductions in plasma [NO] following hemodilution. Therefore, 445 
hemoglobin scavenging of NO appears to be an important factor in the regulation of flow-mediated 446 
dilation and constrains endothelium-dependent NO-mediated vasodilation in otherwise healthy humans. 447 
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Table 1. Brachial hemodynamics prior to and following isovolumic hemodilution 
 Pre Post P-value 
Baseline Diameter (mm) 4.61±0.37 4.51±0.38 0.03 
Peak Diameter (mm) 4.78±0.36 4.95±0.41 0.04 
Delta Diameter (mm) 0.17±0.09 0.44±0.19 <0.01 
Time to Peak Diameter (sec) 42.0±15.7 72.1±45.1 0.03 
    
Response SSAUC-60 806±225 841±267 0.66 
    
Reactive hyperemia total (mL) 21178±7248 31570±13231 0.02 
Reactive hyperemia peak (mL/min) 378±88 464±153 0.056 
Reactive hyperemia 1 min (mL) 13201±3560 18180±6510 0.02 
SRAUC, shear rate area under the curve; SSAUC, shear stress area under the curve. Significance testing 
was conducted with a two tailed paired t-test. 
 
Table 2. Impact of hemodilution on whole blood and plasma viscosity 
 Whole Blood Viscosity Plasma Viscosity 









1 4.28 3.12  1.37 1.16  
2 3.89 2.98  1.29 1.15  
3 4.54 3.45  1.32 1.14  
4 4.17 3.18  1.28 1.18  
5 4.05 2.95  1.37 1.23  
6 4.28 3.28  1.38 1.22  
7 4.22 3.07  1.32 1.10  
Mean 4.20 3.15 <0.001 1.33 1.17 <0.001 
STDEV 0.20 0.17  0.04 0.05  
Significance testing was conducted with a two tailed paired t-test. 
  




Figure 1. Blood gases and nitric oxide metabolites prior to and following hemodilution. All panels 
depict box and whisker plots displaying quartiles. Hemodilution reduced hemoglobin concentration 
([Hb]), viscosity, and arterial oxygen content (CaO2), while the partial pressure of arterial oxygen 
(PaO2) was unaltered. The concentration of whole blood nitric oxide (NO; nitrite, S-nitrosothiols, and 
heme-bound NO) was reduced along with plasma nitrite (NO2
−), plasma S-nitrosothiols (RSNO) and total 
red blood cell NO (nitrite, S-nitrosothiols, and heme-bound NO). *denotes a significant difference from 
pre- to post-hemodilution, P<0.05. A paired two tailed t-test was used for all comparisons in this figure. 
For Panels A-D, n=11 while for Panels E-H, n=10. 
 
Figure 2. Shear stress patterns and flow-mediated dilation prior to and following hemodilution. 
Panel A depicts resting shear stress (SS) patterns pre- and post-hemodilution. Panel B depicts the shear 
stress response to cuff release with pre-hemodilution denoted in the red line and post-hemodilution the 
blue line. The grey vertical lines represent standard deviation. Panel C depicts box and whisker plots 
(quartiles) for shear rate area under the curve (SRAUC) while panel D depicts the shear stress area under 
the curve (SSAUC) pre- and post-hemodilution. Notably, brachial SRAUC was increased post-
hemodilution but SSAUC was not. This highlights the importance of incorporating viscosity measures 
into the shear stimulus for flow-mediated dilation (FMD). Panel E depicts the FMD response pre- and 
post-hemodilution along with the covariate adjusted FMD data. *denotes a significant difference pre- to 
post-hemodilution, P<0.05. A paired two tailed t-test was utilized to compare shear stress (Panel A), 
brachial SRAUC (Panel C), brachial SSAUC (Panel D), and FMD% (Panel E – left side). For the 
“Adjusted” FMD% in Panel E, the diameter change on a logarithmic scale (ln(peak diameter) - 
ln(baseline diameter)) was assessed as the outcome variable in a linear mixed model with 
logarithmically-transformed baseline diameter as well as SSAUC included as covariates. N=11 for all 
comparisons. 
 
Figure 3. Time control flow-mediated dilation study. Panel A depicts whole blood viscosity prior to 
and following the time control rest period. Panel B depicts resting shear patterns prior to and following 
the time control rest period. Panel C depicts shear rate area under the curve (SRAUC), while Panel D 
depicts FMD. A paired two tailed t-test was utilized to compare viscosity (Panel A), shear rate (Panel 
B), brachial SRAUC (Panel C), and FMD% (Panel D – left side). For the “Adjusted” FMD% in Panel D, 
the diameter change on a logarithmic scale (ln(peak diameter) - ln(baseline diameter)) was assessed as 
the outcome variable in a linear mixed model with logarithmically-transformed baseline diameter as 
well as SSAUC included as covariates. N=11 for all comparisons. 
 



